First-in-Human Safety and Tolerability Study of TOP-N53, a NO-Releasing PDE5 Inhibitor, in Healthy Volunteers

This first-in-human Phase I trial demonstrated that the novel NO-releasing PDE5 inhibitor TOP-N53 is safe and well-tolerated in healthy volunteers while inducing sustained, dose-dependent improvements in local skin perfusion, supporting its further development as a treatment for chronic wounds.

The Gist

Imagine you have a garden with a patch of soil that has stopped growing flowers. The problem isn't just that the seeds are bad; it's that the water pipes leading to that specific patch are clogged, and the soil has forgotten how to drink. This is similar to what happens with chronic wounds (like stubborn diabetic ulcers or non-healing sores). The blood vessels are damaged, oxygen can't get through, and the healing process stalls.

Doctors usually try to fix this by giving patients pills that open up blood vessels everywhere in the body. But this is like turning on the main water valve for the entire city just to water one dry flower pot. It works, but it often causes "floods" elsewhere (side effects like headaches, dizziness, or low blood pressure) and doesn't always deliver enough water to the specific spot that needs it.

Enter TOP-N53: The "Smart Sprinkler"

This paper describes a "First-in-Human" study (the very first time a new drug is tested on people) for a new medicine called TOP-N53. Think of TOP-N53 not as a pill, but as a smart, dual-action sprinkler designed to fix that one specific dry patch of soil without flooding the rest of the city.

Here is how it works, using simple analogies:

1. The Two-Pronged Attack

TOP-N53 is a "bifunctional" molecule, which is a fancy way of saying it has two jobs in one package:

• Job A (The Water): It releases Nitric Oxide (NO). Think of NO as a signal flare that tells the blood vessels, "Hey, relax and open up wide!"
• Job B (The Lock): It blocks an enzyme called PDE5. Imagine PDE5 as a "closing door" that usually shuts the blood vessels back down quickly. TOP-N53 jams that door shut, keeping the vessels open longer.

By doing both at the same time, it creates a powerful, long-lasting effect right where it is applied, helping blood flow rush into the wound to speed up healing.

2. The Experiment: Testing the Sprinkler

The researchers wanted to see if this "smart sprinkler" was safe before they tried it on actual wounds. They couldn't test it on open wounds yet because the volunteers were healthy people with perfect skin. So, they had to be clever:

• The Setup: They recruited 29 healthy men.
• The Test: On each man's arm, they gave two tiny injections under the skin (subcutaneous).
  • One arm got the Smart Sprinkler (TOP-N53).
  • The other arm got a Fake Sprinkler (Placebo/Vehicle) that looked and felt exactly the same but had no active medicine.
• The Blinding: Neither the doctors nor the volunteers knew which arm got the real medicine. This is like a blind taste test to ensure the results are honest.

3. The Results: Did it Work?

The study looked at three main things:

• Safety (Did it hurt?): The answer was a resounding YES, it was safe.

  • No one had serious reactions.
  • No one's blood pressure dropped dangerously low (a common side effect of other vasodilators).
  • There were no headaches or dizziness that could be blamed on the drug.
  • Analogy: It was like testing a new fire extinguisher; it put out the "fire" (vasoconstriction) without burning down the house (the rest of the body).

• Local Effect (Did it open the pipes?):

  • Using a special camera called Laser Speckle Contrast Imaging (think of it as a high-tech thermal camera that sees blood flow), they watched the skin around the injection site.
  • At higher doses, the skin around the TOP-N53 injection stayed "warm" and well-perfused for up to 24 hours. The placebo arm didn't show this sustained effect.
  • Analogy: The Smart Sprinkler successfully watered the specific patch of soil for a whole day, while the fake one did nothing.

• Systemic Effect (Did it flood the city?):

  • They checked the volunteers' blood to see if the medicine traveled to the rest of the body.
  • Result: The medicine stayed almost entirely local. It didn't show up in the blood in significant amounts.
  • Analogy: The sprinkler watered the flower pot but didn't leak into the neighbor's yard. This is huge because it means fewer side effects.

4. The "Volume" Surprise

Interestingly, the researchers noticed that just injecting a lot of liquid (even the fake liquid) caused a temporary increase in blood flow. This is likely because the body reacts to the physical poke of a large needle volume. However, the real medicine (TOP-N53) kept the blood flow high for much longer than the fake liquid did, proving the drug itself was doing the work.

The Bottom Line

This study is a major green light. It proves that TOP-N53 is safe for humans and works exactly as designed:

1. It boosts blood flow locally (right where you put it).
2. It leaves the rest of the body alone (no low blood pressure or headaches).

What's Next?
The researchers are now moving to the next phase: testing this on actual patients with chronic wounds (like diabetic foot ulcers) using a gel formulation (like a cream) instead of an injection. If it works there, it could be a game-changer for people whose wounds just won't heal, offering a way to fix the "clogged pipes" without the side effects of current treatments.

In short: They built a targeted, local blood-flow booster that doesn't knock you over, and the first human test proved it's safe to take to the next level.

Technical Summary

1. Problem Statement

Chronic wounds (e.g., diabetic foot ulcers, ischemic ulcers, systemic sclerosis digital ulcers) are characterized by impaired microcirculation, hypoxia, and delayed healing. Current therapeutic strategies face significant limitations:

• Systemic Vasodilators: Oral PDE5 inhibitors (e.g., sildenafil) and IV prostacyclins improve perfusion but require high systemic exposure to reach the wound site, leading to dose-limiting systemic side effects (headache, dizziness, hypotension).
• Topical Limitations: Topical growth factors often suffer from poor tissue penetration and high costs.
• Pathophysiology: Chronic wounds often involve endothelial dysfunction with reduced Nitric Oxide (NO) bioavailability. While PDE5 inhibitors can potentiate the NO/cGMP pathway, their efficacy is limited in environments where NO production is already deficient.

There is a critical unmet need for a locally acting therapy that simultaneously replenishes NO and inhibits its degradation (via PDE5 inhibition) to enhance local perfusion without causing systemic hypotension.

2. Methodology

Study Design:

• Type: First-in-Human (FIH), randomized, double-blind (intra-individual), vehicle-controlled, single ascending dose (SAD) Phase I trial.
• Setting: CRS Clinical Research Services Mannheim GmbH, Germany.
• Participants: 29 healthy male volunteers (aged 20–55, BMI 20–24.9 kg/m²).
• Intervention: Single subcutaneous (SC) injections of TOP-N53 or vehicle (placebo) into the forearm.
  • Intra-individual Blinding: Each participant received both TOP-N53 and vehicle in the same forearm (proximal vs. distal sites, 10 cm apart) to control for individual variability.
  • Dosing: Five ascending dose groups (DG1–DG5) with volumes ranging from 0.1 mL to 1.5 mL, corresponding to TOP-N53 doses of 0.605 µg to 9.075 µg.
• Mechanism of Action: TOP-N53 is a bifunctional molecule that, upon intracellular bioactivation, releases Nitric Oxide (NO) and converts into TOP-52, a potent PDE5 inhibitor. This dual action aims to synergistically increase cGMP levels locally.

Assessments:

• Safety: Local tolerability (erythema, pain, swelling), systemic vital signs (BP, HR), ECG, and laboratory panels over 72 hours.
• Pharmacokinetics (PK): Plasma concentrations of TOP-N53 and metabolite TOP-52 measured via LC-MS/MS (LLOQ: 120 pg/mL).
• Pharmacodynamics (PD): Skin perfusion measured using Laser Speckle Contrast Imaging (LSCI). The primary PD metric was the change in Cutaneous Vascular Conductance ($\Delta$CVC) from baseline over 24 hours.

3. Key Contributions

• Novel Molecule Validation: This study provides the first clinical evidence of the safety and local pharmacodynamic activity of TOP-N53, a molecule designed to overcome the limitations of systemic vasodilators and single-mechanism topical agents.
• Dissociation of Local vs. Systemic Effects: The study successfully demonstrated that a locally applied vasoactive agent can significantly increase local skin perfusion without affecting systemic arterial blood pressure, a critical differentiator from oral PDE5 inhibitors.
• Proof of Concept for "On-Wound" Design: It validates the strategy of using a locally acting, NO-releasing PDE5 inhibitor to treat microvascular dysfunction, supporting the transition to topical formulations for chronic wounds.

4. Key Results

Safety and Tolerability:

• Adverse Events: No serious adverse events (SAEs) or drug-related adverse events occurred.
• TEAEs: Only 5 mild-to-moderate treatment-emergent adverse events (dizziness, headache) were reported across 5 participants; all were deemed unrelated or unlikely related to the drug.
• Local Reactions: No local injection site reactions (pain, erythema, induration) were observed up to 24 hours post-injection.
• Systemic Hemodynamics: No clinically relevant changes in systolic/diastolic blood pressure or heart rate were observed at any dose level (up to 9.075 µg).

Pharmacokinetics (PK):

• Systemic Exposure: Plasma concentrations of both TOP-N53 and its active metabolite TOP-52 remained below the limit of quantification (LLOQ) for the vast majority of participants.
• Implication: This indicates minimal systemic absorption, confirming the drug acts locally. Estimated free plasma concentrations were far below the Minimum Anticipated Biological Effect Level (MABEL) for systemic vasodilation.

Pharmacodynamics (PD):

• Local Perfusion: TOP-N53 induced a sustained, dose-dependent increase in local skin perfusion ($\Delta$CVC) compared to vehicle.
• Effective Doses: Significant trends toward increased perfusion were observed at the two highest doses (4.84 µg and 9.075 µg), with effects lasting up to 24 hours post-injection.
• Statistical Note: While the study was not powered for statistical significance (n=6 per group), the magnitude of the effect (30–48% increase in AUEC for the highest doses vs. vehicle) and the dose-response relationship were clear.
• Vehicle Effect: Higher injection volumes (800 µL and 1500 µL) of the vehicle alone caused a transient increase in perfusion (likely due to axon reflex or excipient effects), but TOP-N53 augmented this effect further.

5. Significance and Conclusion

This study establishes a strong safety and tolerability profile for TOP-N53 in humans. The most significant finding is the complete dissociation between local efficacy and systemic toxicity: TOP-N53 successfully increased local skin blood flow without causing systemic hypotension, a common failure mode for systemic vasodilators.

• Clinical Potential: These findings support the further development of TOP-N53 as a topical treatment for chronic wounds with microvascular dysfunction, such as diabetic foot ulcers and systemic sclerosis digital ulcers.
• Future Directions: The authors note that a Phase 2a trial (NCT06954597) is currently recruiting patients with systemic sclerosis digital ulcers to test a hydrogel-based topical formulation. Future studies will aim to confirm efficacy in patient populations, determine optimal dosing, and assess wound closure rates.

In summary, TOP-N53 represents a promising "on-wound" therapeutic strategy that leverages dual NO-release and PDE5 inhibition to restore local perfusion while minimizing systemic risks.